Interim Analysis of PROMise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib
AUTHORS
Mead, et al
Programs
OPN-2853
Download PDF
OPN-6602, an Orally Bioavailable EP300/CBP Bromodomain Inhibitor, Targets Multiple Myeloma through Suppression of IRF4 and MYC
AUTHORS
Matusow, et al
Programs
OPN-6602
Download PDF
OPN-9840, a non-covalent potent pan-TEAD inhibitor, exhibits single agent efficacy in preclinical malignant mesothelioma models
AUTHORS
Chen, et al
Programs
OPN-TEAD
Download PDF
OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC
AUTHORS
Matusow, et al
Programs
OPN-6602
Download PDF